Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

(2012) Carol Aghajanian et al.   JOURNAL OF CLINICAL ONCOLOGY

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

(2011) Robert A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

(2011) Timothy J. Perren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic Importance of Vascular Endothelial Growth Factor-A Expression and Vascular Endothelial Growth Factor Polymorphisms in Epithelial Ovarian Cancer

(2010) Maja Patricia Smerdel et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases

(2010) Edouard Lecarpentier et al.   INVESTIGATIONAL NEW DRUGS

Ultimate Fate of the Leaking Intestinal Anastomosis: Does Leak Mean Permanent Stoma?

(2010) Todd D. Francone et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

(2010) Ignace Vergote et al.   NEW ENGLAND JOURNAL OF MEDICINE

The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer

(2009) X B Trinh et al.   BRITISH JOURNAL OF CANCER

The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: A retrospective cohort study

(2009) Gregory P. Sfakianos et al.   GYNECOLOGIC ONCOLOGY

Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma

(2009) John P. Diaz et al.   GYNECOLOGIC ONCOLOGY

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

(2009) Noriyuki Katsumata et al.   LANCET

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

(2009) Sanjaykumar Hapani et al.   LANCET ONCOLOGY

Vascular Endothelial Growth Factor Expression in Ovarian Cancer: A Model for Targeted Use of Novel Therapies?

(2008) T. J. Duncan et al.   CLINICAL CANCER RESEARCH

Bowel perforation in non-small cell lung cancer after bevacizumab therapy

(2008) Elisabeth Schellhaas et al.   INVESTIGATIONAL NEW DRUGS

Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation

(2008) J. Tol et al.   INVESTIGATIONAL NEW DRUGS

Mechanical Obstruction of the Small Bowel and Colon

(2008) Mitchell S. Cappell et al.   MEDICAL CLINICS OF NORTH AMERICA

Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion

(2008) D. Belotti et al.   MOLECULAR CANCER RESEARCH